Parkinson's disease (PD) is a multisystem disorder with characteristics of a chronic
inflammatory disease. To develop effective immunomodulatory interventions to combat PD …

Agents suppressing microglial activation are attracting attention as candidate drugs for
neuroprotection in Parkinson's disease (PD): While different mechanisms including …

Parkinson's disease (PD) is the second most common age-associated neurodegenerative
disorder and is characterised by progressive loss of dopamine neurons in the substantia …

Evidence has been accumulated showing that inflammatory and cell death pathways are
altered both in brain and periphery during Parkinson disease (PD). Neuronal loss in PD is …

Background Parkinson's disease (PD) is a neurodegenerative disorder with progressive loss
of dopaminergic (DA) neurons. Systemic inflammation is shown to initiate and exacerbate …

Over the last decade the important concept has emerged that microglia, similar to other
tissue macrophages, assume different phenotypes and serve several effector functions …

Idiopathic Parkinson's disease is characterized by a progressive loss of dopaminergic
neurons, but the exact disease aetiology remains largely unknown. To date, Parkinson's …

Microglia, often described as the brain-resident macrophages, play crucial roles in central
nervous system development, maintenance, plasticity, and adaptation to the environment …

Neuroinflammation is a pathological hallmark in Parkinson's disease (PD) and amyotrophic
lateral sclerosis (ALS), and is characterized by activated microglia and infiltrating T cells at …

Neuroinflammation has received increased attention as a target for putative neuroprotective
therapies in Parkinson's Disease (PD). Two prototypic pro-inflammatory cytokines interleukin …